IDH-mutant astrocytomas exhibit a comparatively higher responsiveness to checkpoint immunotherapy compared to IDH-mutant oligodendrogliomas, primarily due to the reduced expression of PD-L1 and other checkpoint molecules in the latter. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).